The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity.

Trial Profile

The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2012

At a glance

  • Drugs Fluoxetine (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole
  • Indications Depressive disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 19 Jun 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
    • 19 Jun 2012 Actual patient number added 36 according to ClinicalTrials.gov.
    • 19 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top